Full Press Release Details
Novavax Announces Leadership Change
GAITHERSBURG, Md., October 13, 2017 --
Novavax, Inc., (Nasdaq:NVAX) announced today that Barclay A. "Buck" Phillips has submitted his resignation as Senior
Vice President, Chief Financial Officer (CFO) and Treasurer, to pursue an expanded opportunity in the industry. Mr. Phillips will
step down effective November 10, 2017, and will provide financial, accounting and transition services as a consultant to Novavax
until December 31, 2017. Mr. Erck will act as the interim CFO pending completion of a search for a new Chief Financial Officer.
"Buck has been instrumental in a
number of significant Novavax accomplishments, and we thank him for all his contributions over the last four years. We wish him
all the best in his new endeavors," said Stanley C. Erck, President and CEO of Novavax.
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage
biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles
and Matrix-M adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe
and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.
Andrea N. Flynn, Ph.D.
Director, Investor & Media Relations